期刊文献+

5-氮杂胞苷对RASSF1去甲基化与胃癌细胞增殖和凋亡的关系 被引量:1

下载PDF
导出
摘要 目的:探讨5-氮杂胞苷对RASSF1基因去甲基化与胃癌细胞增殖和凋亡的关系。方法将SGC7901胃癌细胞分为AZA组(5-氮杂胞苷处理)和CON组(未用5-氮杂胞苷处理),比较两组细胞RASSF1基因启动子甲基化、基因表达、细胞周期和凋亡的差异。结果 CON组SGC7901胃癌细胞RASSF1基因启动子MSP处于甲基化状态,AZA组胃癌细胞未检测到甲基化,AZA组RASSF1基因mRNA和蛋白质表达水平高于CON组细胞。AZA组SGC7901胃癌细胞G0/G1期和凋亡率高于CON组细胞(P〈0.05),S期、G2/M期和PI低于CON组细胞(P〈0.05)。结论5-氮杂胞苷可逆转胃癌细胞RASSF1基因启动子甲基化状态,使沉默的RASSF1基因重新获得表达而抑制胃癌细胞的增殖并促进其凋亡。 Objective To study the effects of 5-azacytidine’s demethylation for RASSF1 gene on gastric cancer cell’s proliferation and apoptosis. Methods SGC7901 gastric cancer cells were divided into CON group(without 5-azacytidine treatment) and AZA group(with 5-azacytidine treatment). The differences of RASSF1 gene promoter’s methylation status,mRNA and protein expressions,cell cycle and apoptosis were compared. Results The RASSF1 gene was methylated in CON group with inhibited mRNA and protein expressions while they were reversed in AZA group. The S phase、G2/M phase and PI in AZA group were lower than in CONgroup,while the G0/G1 phase and apoptosis rates were higher. Conclusion 5-azacytidine could reverse RASSF1 gene promoter’s methylation and silent gene expressions,which inhibits gastric cancer cell’s proliferation and promote apoptosis.
出处 《浙江临床医学》 2014年第10期1537-1539,共3页 Zhejiang Clinical Medical Journal
基金 湖北省自然科学基金项目(2013CFB115)
关键词 胃癌 5-氮杂胞苷 RASSF1 甲基化 细胞增殖 凋亡 Gastric cancer 5-azacytidine RASSF1 Methylation Cell proliferation Apoptosis
  • 相关文献

参考文献11

二级参考文献71

  • 1Xiao-UXu,JianYu,Hong-YuZhang,Meng-HongSun,JunGu,XiangDu,Da-RenShi,PengWang,Zhen-HuaYang,Jing-DeZhu.Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis[J].World Journal of Gastroenterology,2004,10(23):3441-3454. 被引量:43
  • 2张剑英,李智.RASSF1基因与肿瘤的关系[J].国外医学(临床生物化学与检验学分册),2005,26(2):120-122. 被引量:7
  • 3Issa J P.DNA methylation as a therapeutic target in cancer[J].Clin Cancer Res, 2007,13 (6) : 1634-1637.
  • 4Ellis L,Atadja P W,Johnstone R W,Epigenetics in cancer: target- ing chromatin modifications[J].Mol Cancer Ther, 2009,8 ( 6 ) : 1409-1420.
  • 5Kaminskas E,Farrell A T,Wang Y C,et al.FDA drug approval sum- mary :azacytidine(5-azacytidine, vidaza) for injectable suspension[J].On- cologist,2005,10(3) : 176-182.
  • 6Fenaux P, Mufti G J, Hellstrooro-Lindberg E,et al.Efficacy of azac- itidine compared with that of conventional care regimens in the treat- ment of higher-risk royelodysplastic syndromes: a randomised,open-la- bel,phase 111 study[J].Lancet Oncol,2009,10(3) :223-232.
  • 7Liu Y, Johnson S M, Fedoriw Y, et aI.Expression of p 16INK4a pre- vents cancer and promotes aging in |ymphocytes[J].B|ood,2011,117(12) : 3257-3267.
  • 8Lin Y, Hupp T R,Stevens C.Death-associated protein kinase (DAPK) and signal transduction: additional roles beyond cell death[J]. FEBS J, 2010,277( 1 ) :48-57.
  • 9Qian J,Wang Y L,Lin J,et al.Aberrant methylation of the death- associated protein kinase 1 (DAPK1) CpG island in chronic myeloid leukemia[J].Eur J Haematol, 2009,82 (2) : 119-123.
  • 10Liu L, Gerson S L.Targeted modulation of MGMT:clinical implica- tions [J].Clin Cancer Res, 2006,12(2) : 328-331.

共引文献19

同被引文献15

  • 1倪娟,陈海燕,曹能,周滔,薛京伦,汪旭.不同氧化态叶酸对人成淋巴细胞系基因组DNA甲基化水平的影响[J].肿瘤防治研究,2014,41(3):256-259. 被引量:4
  • 2NISHIOKA C, IKEZOE T, YANG J, et al. Down regulation of miR-217 correlates with resistance of Ph( + ) leukemia cells to ABL tyrosine kinase inhibitors [ J ]. Cancer Sci, 2014,105 (3) :297-307.
  • 3SCHNEIDER D T, CALAMINUS G,KOCH S, et al. Epidemio-logic analysis of 1,442 children and adolescents registered in the German germ cell tumor protocols [ J ]. Pediatr Blood Canc- er ,2004,42 ( 2 ) : 169-175.
  • 4LI W, ZHENG J, DENG J, et al. Increased levels of the long intergenic non-protein coding RNA POU3F3 promote DNA methylation in esophageal squamous cell carcinoma cells [ J ]. Gastroenterology, 2014 , 146 (7) : 1714-1126.
  • 5VENTHAM N T, KENNEDY N A, NIMMO E R, et al. Beyond gene discovery in inflammatory bowel disease: the emerging role of epigenetics [ J ]. Gastroenterology, 2013,145 ( 2 ) : 293- 308.
  • 6BEN GACEM R, BEN ABDELKRIM O,ZIADI S,et al. Meth- ylation of miR- 124a- 1, miR- 124a- 2, and miR- 124a- 3 genes correlates with aggressive and advanced breast cancer disease [ J ]. Tumour Biol, 2014,35 ( 5 ) :4047-4056.
  • 7TELLEZ C S,GRIMES M J,PICCHI M A,et al. SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome [ J ]. Int J Caneer, 2014,135 ( 9 ) : 2223- 2231.
  • 8崔鹤,樊红.DNMT 3A在肿瘤发生中表遗传调控作用的研究进展[J].东南大学学报(医学版),2012,31(4):508-511. 被引量:1
  • 9孙丽,于大海,殷海涛,曹苏生,卓士超,魏玲,刘艳华,孙三元.乳腺癌原发灶与复发转移灶中雌激素受体表达及雌激素受体基因甲基化改变的临床意义[J].中华肿瘤杂志,2014,36(2):128-131. 被引量:9
  • 10郭姗琦,赵海丰,张翼鷟.恶性淋巴瘤的表观遗传调控与治疗[J].中华肿瘤杂志,2014,36(3):161-164. 被引量:6

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部